Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: FGN
1 year chart More charts
digital-look imported chart image
Deal FGN Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
digital-look imported chart image
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Futuragene
www.futuragene.com
Deal Futuragene Tax Free* Losses can exceed
your initial deposit *subject to change and depends on individual circumstances.

Futuragene is a agricultural biotechnology company focused on the development and commercialisation of genetically modified plants for improving and protecting yields, and enhancing processability and environmental sustainability in the forestry, biofuels, biopower and agricultural sectors.

Full Futuragene profile here
Pdf

FuturaGene unit in collaboration deal with Oregon State University

May 11 2009, 11:22am FuturaGene unit in collaboration deal with Oregon State University

FuturaGene PLC (AIM: FGN)  said its unit CBD Technologies Ltd has entered into a collaborative agreement with Oregon State University under which it will provide professor Steven Strauss’ research group at the Forest Biotechnology department with a proprietary eucalyptus clone and a highly efficient eucalyptus transformation protocol.

The collaboration will facilitate rapid and efficient evaluation of genes for flowering control and other biosafety aspects of tree modification.

In addition CBD Tech plans to join the Tree Biosafety and Genomics Research Cooperative (TBGRC), an internationally recognised tree research consortium that has been working with forest industries on tree biotechnology for 15 years and which is directed by Professor Strauss.

Although eucalyptus is the most widely planted commercial plantation tree species for pulp and paper production in the world, this species is notoriously difficult to transform, FurturaGene said in a statement.

Thus, the supply of a proprietary clone and transformation method from the company to a public research institute, under appropriate material usage and confidentiality provisions, represents a significant contribution to accelerating public research and development in this species, it added.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.